Korean J Intern Med.  2007 Mar;22(1):24-27. 10.3904/kjim.2007.22.1.24.

Remission of intestinal Behcet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab)

• Lee JH
• Kim TN
• Choi ST
• Jang BI
• Shin KC
• Lee SB
• Shim YR

• KMID: 1717990
• DOI: http://doi.org/10.3904/kjim.2007.22.1.24

Abstract

Behcet's disease (BD) is a chronic relapsing multisystem disease characterized by oral ulceration, genital ulceration and ocular lesions. Gastrointestinal involvement is rare, often difficult to treat and associated with a high mortality rate. We treated a 47-year-old Korean man with BD who had a recurrent intestinal ulcer with tumor necrosis factor alpha antibody (infliximab); he initially underwent right hemicolectomy due to uncontrolled intestinal bleeding. For patients with intestinal BD who fail to respond to conventional treatment, infliximab may be a safe and effective new therapeutic option.

Keyword

Behcet syndrome; Tumor necrosis factor-alpha; Infliximab

MeSH Terms

Tumor Necrosis Factor-alpha/*therapeutic use
*Treatment Outcome
Remission Induction
Middle Aged
Male
Humans
Gastrointestinal Diseases/*drug therapy/etiology/surgery
Gastrointestinal Agents/*therapeutic use
Disease Progression
Colectomy
Behcet Syndrome/*drug therapy/physiopathology/surgery
Antibodies, Monoclonal/*therapeutic use